Oncologist

Biography

Prof. Dr. Hab. Med. Raanan Berger is the Director of the Oncology Center, a senior oncologist and radiotherapist, and the head of the research center at the Institute of Oncology and Radiotherapy at Sheba Medical Hospital. He holds a PhD in Medical Sciences and a Doctor of Philosophy degree from the Sackler School of Medicine at Tel Aviv University. He is also a member of ESMO and ASCO.

Prof. Berger initiated and established a support service at the Institute of Oncology, aiming to provide patients and their families with a multisystemic treatment environment. Patients receive not only state-of-the-art medical solutions, but also support from experienced psychologists and social workers who offer an individual approach to patients and their family members.

Prof. Berger is the leader of the uro-genital oncology program and conducts basic and translational laboratory research on molecular mechanisms in the process of prostate and breast cancer development. Prof. Berger is the co-author of 20 peer-reviewed scientific articles.

Diseases and Treatment

  • Oncology
  • Uro-genital Oncology
  • Prostate Cancer
  • Prostate and Breast Cancer Development Processes


Positions

  • Director of the Oncology Center
  • Senior Oncologist and Radiotherapist
  • Member of ESMO and ASCO
  • Senior Lecturer at the Sackler School of Medicine at Tel Aviv University


Education and Training

  • PhD in Medical Sciences and Doctor of Philosophy from the Sackler School of Medicine, TAU. Clinical training in clinical oncology and radiotherapy at Sheba.
  • Postdoctoral fellowship at the Dana-Farber Cancer Institute at Harvard Medical School.
  • Combination of clinical work in treating patients with prostate cancer (with Dr. Philip Kantoff) with basic research in Dr. William C. Hahn’s laboratory.


Publications

  • Classification of High-Risk Prostate Cancer vs. Very High-Risk Prostate Cancer: Does It Matter for Outcomes in Conformal Radiotherapy and Androgen Deprivation?
  • Inheritance of harmful mutations in both BRCA1 and BRCA2 in an international study conducted on a sample of 32,295 women.